MX2022006147A - Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1. - Google Patents

Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.

Info

Publication number
MX2022006147A
MX2022006147A MX2022006147A MX2022006147A MX2022006147A MX 2022006147 A MX2022006147 A MX 2022006147A MX 2022006147 A MX2022006147 A MX 2022006147A MX 2022006147 A MX2022006147 A MX 2022006147A MX 2022006147 A MX2022006147 A MX 2022006147A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
combination
cancer treatment
pdl1
Prior art date
Application number
MX2022006147A
Other languages
English (en)
Spanish (es)
Inventor
Ye Liu
Beibei Jiang
Xiaomin Song
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of MX2022006147A publication Critical patent/MX2022006147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022006147A 2019-11-21 2020-11-19 Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1. MX2022006147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019120055 2019-11-21
PCT/CN2020/130075 WO2021098774A1 (en) 2019-11-21 2020-11-19 Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies

Publications (1)

Publication Number Publication Date
MX2022006147A true MX2022006147A (es) 2022-06-17

Family

ID=75981031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006147A MX2022006147A (es) 2019-11-21 2020-11-19 Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.

Country Status (12)

Country Link
US (1) US20230212291A1 (https=)
EP (1) EP4061850A4 (https=)
JP (1) JP2023503396A (https=)
KR (1) KR20220103708A (https=)
CN (1) CN115151563A (https=)
AU (1) AU2020386583A1 (https=)
BR (1) BR112022009147A2 (https=)
CA (1) CA3156931A1 (https=)
IL (1) IL293119A (https=)
MX (1) MX2022006147A (https=)
WO (1) WO2021098774A1 (https=)
ZA (1) ZA202204423B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
CN121285385A (zh) 2023-05-12 2026-01-06 金麦安博股份有限公司 能够与ox40结合的抗体、其变体及其用途
WO2024240247A1 (en) * 2023-05-25 2024-11-28 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies
TW202540189A (zh) * 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800503T1 (it) * 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
EA034666B1 (ru) * 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
AU2014364606A1 (en) * 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
TWI726608B (zh) * 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
TN2019000101A1 (en) * 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
WO2017021911A1 (en) * 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
CN111542544A (zh) * 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
CN112566935B (zh) * 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法

Also Published As

Publication number Publication date
WO2021098774A1 (en) 2021-05-27
CN115151563A (zh) 2022-10-04
US20230212291A1 (en) 2023-07-06
EP4061850A4 (en) 2024-03-20
EP4061850A1 (en) 2022-09-28
AU2020386583A1 (en) 2022-06-02
CA3156931A1 (en) 2021-05-27
KR20220103708A (ko) 2022-07-22
BR112022009147A2 (pt) 2022-07-26
JP2023503396A (ja) 2023-01-30
IL293119A (en) 2022-07-01
ZA202204423B (en) 2023-01-25

Similar Documents

Publication Publication Date Title
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
MX2022006147A (es) Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
MY205758A (en) Anti-nkg2a antibodies and uses thereof
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
ZA201803079B (en) Anti-dr5 antibodies and methods of use thereof
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2021008888A (es) Anticuerpos anti-tau humanizados.
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA202090791A1 (ru) Агонистические антитела против cd40
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2022006148A (es) Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit.
MX2020008122A (es) Anticuerpos anti-pd-1.
ZA202008095B (en) Humanized antibodies against psma
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
MX2023008597A (es) Metodos de tratamiento del cancer usando anticuerpos anti-tigit en combinacion con anticuerpos anti-pd1.